Abivax SA (ABVX) will be added to the Nasdaq Biotechnology Index (NBI) effective prior to the market open on Monday, December 22, 2025, following an announcement made on December 18, 2025.
The inclusion follows the company’s successful Phase 3 ABTECT induction trials for ulcerative colitis, which met primary endpoints and demonstrated clinically meaningful remission rates. It also comes after a July 2025 equity offering that raised approximately $700.3 million, strengthening the balance sheet and extending the cash runway through the fourth quarter of 2027.
Financially, Abivax reported a net loss of €254.1 million for the first nine months of 2025, up from €136.9 million a year earlier, while operating losses widened to €174.4 million from €130.2 million. Research and development expenses rose to €133.4 million, and general and administrative costs increased to €41.8 million, reflecting the company’s continued investment in its lead candidate, obefazimod.
Chief Financial Officer Didier Blondel said the NBI inclusion “marks a significant milestone for Abivax, validating the progress we have made with obefazimod and reinforcing our visibility within the global biotechnology community.”
Being listed in the NBI is expected to enhance Abivax’s profile among biotech investors, improve trading liquidity, and attract broader analyst coverage, positioning the company for future regulatory submissions and potential market approval of obefazimod in the second half of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.